SCHEMBL22757697

SCHEMBL22757697

C[C@H](N)c1cccc(Cl)c1C(=O)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 5/20 0.50
JAK1 P23458 3/20 0.50
JAK2 O60674 3/20 0.50
ITGB1 P05556 2/20 0.50
ITGA4 P13612 2/20 0.50
CYP3A4 P08684 2/20 0.50
PTGS2 P35354 1/20 0.49
KMT2A Q03164 1/20 0.49
EGFR P00533 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
NFKB1 P19838 1/20 0.46
PNMT P11086 1/20 0.46
LMNA P02545 2/20 0.45
ALDH1A1 P00352 2/20 0.45
GLA P06280 1/20 0.45
GAA P10253 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154853 0.81 TYK2 (0.71) TYK2JAK1JAK2CYP3A4PTGS2
SCHEMBL28503296 0.80 TAAR1 (0.50) TYK2JAK1JAK2ITGB1ITGA4
SCHEMBL29120503 0.79 ITGB1 (0.47) TYK2JAK1JAK2ITGB1ITGA4
SCHEMBL10355098 0.78 TYK2 (0.45) TYK2JAK1JAK2ITGB1ITGA4
SCHEMBL14991989 0.77 JAK1 (0.75) TYK2JAK1JAK2CYP3A4PTGS2
SCHEMBL30230787 0.77 TYK2 (0.75) TYK2JAK1JAK2ITGB1ITGA4
SCHEMBL9884060 0.77 TYK2 (0.75) TYK2JAK1JAK2ITGB1ITGA4
SCHEMBL3791414 0.75 SMO (0.61) TYK2JAK1JAK2CYP3A4KMT2A
SCHEMBL2168022 0.75 TYK2 (0.58) TYK2JAK1JAK2CYP3A4PTGS2
SCHEMBL10362255 0.75 TYK2 (0.48) TYK2JAK1JAK2ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312718-B2 Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one INFINITY PHARMACEUTICALS, INC. (US) 2022-04-26 US disclosed
US-20200385388-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES INFINITY PHARMACEUTICALS, INC. 2020-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312718-B2 Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one PIK3CA, AKT3, PIK3CD TYK2 1730/4885JAK1 171/4885JAK2 231/4885
US-20200385388-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES PIK3CA, PDPK1, AKT3 TYK2 972/4885JAK1 207/4885JAK2 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.